Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | F2R | P25116 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27721355 | 0.89 | ITGB3 (0.41) | ITGB3ITGA2BF2RMCL1 | |
| SCHEMBL4718414 | 0.85 | ITGB3 (0.33) | ITGB3ITGA2BF2R | |
| SCHEMBL27743968 | 0.82 | ITGB3 (0.36) | ITGB3ITGA2BF2RMCL1 | |
| SCHEMBL28170568 | 0.82 | ITGB3 (0.37) | ITGB3ITGA2BF2RMCL1 | |
| SCHEMBL1007623 | 0.80 | ITGB3 (0.34) | ITGB3ITGA2BF2R | |
| SCHEMBL2484846 | 0.80 | BRD4 (0.37) | ITGB3ITGA2BF2R | |
| SCHEMBL4791077 | 0.80 | ITGB3 (0.41) | ITGB3ITGA2BF2R | |
| SCHEMBL2447521 | 0.80 | ITGB3 (0.46) | ITGB3ITGA2BF2R | |
| SCHEMBL7455213 | 0.79 | ITGB3 (0.31) | ITGB3ITGA2BF2R | |
| SCHEMBL4719202 | 0.78 | ITGB3 (0.35) | ITGB3ITGA2BF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109369513-A | A kind of FBDD often uses the preparation method of molecule fragment | 都创(上海)医药科技有限公司 | 2019-02-22 | — | — | CN | claimed |
| CN-110291090-A | Bentyl as novel jak kinase inhibitor | 利奥制药有限公司 | 2019-09-27 | — | — | CN | disclosed |
| CN-109563085-A | piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109369513-A | A kind of FBDD often uses the preparation method of molecule fragment | 都创(上海)医药科技有限公司 | 2019-02-22 | — | — | CN | disclosed |
| CN-105102456-B | Azaquinazoline inhibitors of atypical protein kinase C | 癌症研究技术有限公司 | 2017-11-14 | — | — | CN | disclosed |
| CN-104955824-B | It is used as the aminopyrimidine compounds of the inhibitor of the EGFR mutant containing T790M | 豪夫迈·罗氏有限公司 | 2017-09-22 | — | — | CN | disclosed |
| CN-103249732-B | The bacterial topoisomerase II of suppression 2-ethyl carbamyl amino-1,3-benzothiazole-5-base | 生物区欧洲有限公司 | 2016-08-10 | — | — | CN | disclosed |
| CN-105764887-A | Nitrogen-containing saturated heterocyclic compound | 住友化学株式会社 | 2016-07-13 | — | — | CN | disclosed |
| US-8513237-B2 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-08-20 | — | — | US | disclosed |
| CN-101277700-B | Pyrimidine compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV | 2013-02-20 | — | — | CN | disclosed |
| WO-2010053438-A1 | MODULATORS OF AMYLOID BETA. | ASTRAZENECA AB (SE) | 2010-05-14 | — | — | WO | disclosed |
| CN-101277700-A | Pyrimidine compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-01 | — | — | CN | disclosed |
| EP-1928461-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-11 | — | — | EP | disclosed |
| EP-1485354-B1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007019083-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | WO | disclosed |
| CN-1882590-A | Fused heterocyclic compounds as serotonin receptor modulators | JOHNSON & JOHNSON (BE) | 2006-12-20 | — | — | CN | disclosed |
| US-20050171347-A1 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-04 | — | — | US | disclosed |
| EP-1485354-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076401-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
| CN-1113895-C | Growth hormone secretagogues | PFIZER (US) | 2003-07-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171347-A1 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | ITGB3 3410/4885ITGA2B 2791/4885F2R 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.